(51) INTL.CL.⁵ C12N-015/12; C12N-015/11; A01K-067/027; G01N-033/68;
               C07K-015/06

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Transgenic Non-Human Animal Carrying a Non-Infectious
     HIV Genome

(72) Jolicoeur, Paul - Canada ;

(73) L`Institute de Recherches Cliniques de Montréal - Canada
     ;

(57) 14 Claims

Notice: The specification contained herein as filed

Canada

CCA 3254 (10-89) 41

Transgenic Non-Human Animal Carrying A Non-
infectious HIV Genome

Abstract of the Disclosure

5   Disclosed herein is a transgenic non-human
animal carrying a transgene which expresses non-
infectious   HIV-1   ribonucleic   acid   and
complementary   proteins   thereof.   Among   the
expressed proteins, which can be found in the
10   milk, serum and several tissues, are the gag and
envelope proteins.   The transgenic animal is
useful   as   a   source   for   obtaining   the
complementary proteins, and as an animal model to
study HIV host cell interactions and to evaluate
15   anti-HIV drugs.

Transgenic Non-Human Animal Carrying A Non-infectious HIV Genome

5   Field of Invention

This invention relates to a transgenic non-human mammal carrying a transgene which expresses a non-infectious human immunodeficiency virus ribonucleic acid (HIV-1 RNA) and complementary
10   proteins translated therefrom, to recombinant molecules containing the genetic sequence of the transgene, to a process for producing the transgenic mammal, and to methods of evaluating the pharmacokinetic effect of an agent on the
15   expressed ribonucleic acid and/or proteins to determine the therapeutic value of the agent.

Background of the Invention

In 1983, a retrovirus, known as human immunodeficiency virus type 1 (HIV-1), was
20   established as a causitive agent of acquired immune deficiency syndrome (AIDS), see R.C. Gallo and L. Montagnier, Scientific American, 259 (4), 40 (1988). This virus has become a pestilence of alarming proportion. More recently, the closely
25   related virus, human immunodeficiency virus type 2 (HIV-2) has been identified as a second causative agent of AIDS.

The identification of human immunodeficiency virus (HIV) as a causative agent and the
30   development of methods to grow the virus in quantity have resulted in the discovery of compounds which inhibit the replication of HIV in vitro. The most important class of inhibitor

compounds identified in this manner is a group of dideoxynucleosides of which 3′-azido-3′-deoxythymidine (known also as zidovudine or AZT) is used therapeutically to manage certain patients with symptomatic HIV infections. This class of compounds has been found to interfere with the life cycle of HIV by inhibiting reverse transcriptase. This enzyme converts viral RNA to double-stranded deoxyribonucleic acid (DNA) and as such is an essential enzyme for HIV replication. In addition to inhibiting reverse transcriptase, other stages of the HIV life cycle have been identified as targets for developing anti-AIDS drugs. One target that is receiving increased attention is an HIV-encoded enzyme known as HIV protease. This enzyme, like the reverse transcriptase, is encoded by the gag-pol gene and is essential for HIV growth. It is responsible for effecting certain cleavages within the gag (p55) or gag-pol (p180) protein precursors to release structural proteins and enzymes, including itself, found in mature infectious virions. Soon after infection, the protease may cleave the core nucleocapsid, thus triggering conformational changes of the ribonucleoprotein substrate and activating DNA synthesis. Thus, inhibitors of HIV protease may block several stages in the HIV life cycle. For a recent review on HIV-protease inhibitors, see B.M. Dunn and J. Kay, Antiviral Chemistry & Chemotherapy, 1, 3, (1990).

Notwithstanding the progress that has been made in the causes and treatment of AIDS, better small animal models are needed to study HIV infections and to evaluate potential drugs and vaccines. The need has resulted in the

development of two small animal models based on
severe combined immunodeficient (SCID) mice,
D.E. Mosier et al., Nature, <u>335</u>, 256 (1988) and
J.M. McCune et al., Science, <u>241</u>, 1632 (1988).

5   These small animal models have the potential of
being used for evaluating anti-AIDS drugs and
vaccines. However, there is still a need for a
small animal model to study HIV/host cell
interactions and to screen for anti-HIV drugs.

10   The present invention offers to fulfil the
latter need by providing a transgenic non-human
mammal, for example a mouse or a rat, which
expresses non-infectious HIV RNA, and the
structural proteins, regulatory proteins and

15   enzymes translated thereform, and which can
heritably transmit the transgene to its progeny.

The procedure for producing a transgenic
animal is known in the art; for example, see
B. Hogan et al., "Manipulating the Mouse Embryo:

20   A Laboratory Manual", Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, USA, 1986 and
T.E. Wagner and P.C. Hoppe, US patent 4,873,191,
issued October 10, 1989. However, the prior art
also teaches that it is difficult, and not

25   precisely understood how, to obtain an animal
which carries a transgene functioning in a
suitable physiological environment and in a
desired manner, and which can produce offspring
expressing the gene. The desired gene expression

30   can be nullified if the cloned DNA is integrated
into a region of the animal's chromosome that
modifies its expression, or if it undergoes
mutation or rearrangement in the process of being
integrated into the chromosome; see, for example,

35   H.Van der Putten et al., Mol. Gen. Genetic, <u>198</u>,

128 (1984). Accordingly, a significant advance in the art of retrovirus transgenic animals, specifically HIV transgenic animals, can be realized by following the teaching of the present invention.

Previously reported production of transgenic animals include:

(a) & (b) transgenic mice containing human globin genes, T.A. Stewart et al., Science, 217, 1046 (1982) and E.F. Wagner et al., Proc. Natl. Acad. Sci. USA, 78, 5016 (1981);

(c) transgenic mice containing the human growth hormone gene fused to a metalothionein promoter sequence; R.D. Palmiter et al., Science, 222, 809 (1983);

(d) transgenic mice with a recombinant gene containing the rat elastase I promoter and the codons for human growth hormone, D.M. Ornitz et al., Nature, 313, 600 (1985);

(e) transgenic mice containing the human insulin gene, R.F. Selden and H.M. Howard, PCT patent application WO 87/07298, published December 3, 1987;

(f) several transgenic mice cited in a review by G. Skangos and C. Bieberich, Advances in Genetics, 24, 285 (1987);

(g) several transgenic mice cited in a review by R.M. Strojek et al. entitled "The Use of Transgenic Animal Techniques for Livestock Improvement" in "Genetic Engineering: Principles

5

and Methods", J.K. Setlow, Ed., Vol. 10, New York, NY, USA, 1988;

(h) transgenic non-human animals having a transgene with an activated oncogene sequence, P. Leder and T.A. Stewart, US patent 4,736,866, issued April 12, 1988;

(i) several transgenic animals cited in a review by J. Van Brunt, Bio/Technology, 6, 1149 (1988);

(j) transgenic animals, containing hormone encoded genes, from which hormones can be harvested, R.M. Evans et al., US patent 4,870,009, issued September 26, 1989;

(k) transgenic animals containing a gene capable of producing recombinant proteins in the animal's milk, H. Meade and N. Lonberg, US patent 4,873,316, issued October 10, 1989; and

(l) transgenic mice, useful for analysis of high growth, having recombinant genes comprising the regulatory elements involved in the expression of hair specific genes, A.R. McNab et al., Canadian patent application 2004156, published May 31, 1990.

Previous reports of transgenic mice carrying all or part of the HIV-1 genome include:

(a) a line of transgenic mice carrying only the long terminal repeat (LTR) of HIV fused to the chloramphenicol acetyl transferase (CAT) reporter gene, which were mated to transgenic mice of the opposite sex carrying the HIV-1 tat gene fused to a control element of the murine $A\alpha$ crystallin

gene to give progeny carrying both genes; hence, only a small portion of the HIV-1 genome is involved, J.S. Khillan et al., Nucleic Acids Res., 16, 1423 (1988);

(b) transgenic mice having the HIV-1 tat gene linked to the HIV-1 LTR in the absence of other parts of the HIV-1 genome and which developed skin lesions resembling Kaposi's sarcoma, J. Vogel et al., Nature, 335, 606 (1988);

(c) a single founder line of transgenic mice carrying a complete HIV-1 proviral genome wherein the offspring developed a disease syndrome resembling some aspects of the symptoms of AIDS patients, and marked by the presence of HIV in the tissues of the offspring and premature death thereof, J.M. Leonard et al., Science, 242, 1665 (1988);

(d) four lines of transgenic mice containing the HIV-1 LTR linked to the CAT reporter gene but no other parts of the HIV-1 genome and for which CAT activity was observed among mononuclear cells and maximally in Langerhans' cells, J. Leonard et al., AIDS Res. Hum. Retrovirus, 5, 421 (1989);

(e) trangenic progeny from three founder mice bearing chromosomally integrated copies of partial HIV-1 proviral DNA (rendered non-infectious by deletion of the gag-pol sequences) and which developed glomerulosclerosis, P. Dickie et al., Sixth International Conference on AIDS, San Francisco, Vols 1-3, abstract Th.A. 290 (1990);

(f)   transgenic mice carrying HIV TAT and NEF
genes under control of the HIV LTR, but no other
parts of the HIV genome, as well as two
transgenic founders carrying the HIV NEF gene
construct (without TAT), J. Dinchuk et al., Sixth
International Conference on AIDS, San Francisco,
Vols. 1-3, abstract Th.A. 291 (1990);

(g)   transgenic mice bearing the LTR of HIV (but
no other parts of the HIV-1 genome) fused to the
reporter gene CAT, one line of which showed CAT
activity in the cerebellum, E. Harlan and
O.P. Rakash, Society for Neuroscience Abstracts,
Vol. 16, 353 (1990), abstract 154.1; and

(h)   three lines of transgenic mice carrying a
partial HIV genome comprising the HIV-1 LTR fused
to the simian virus 40 early region, for which
the transgene was observed in the lymphoid tissue
and skin of the mice, J. Skowronski, J. Virol.,
65, 754 (1991).

        The transgenic animal of the present
application is distinguished from the transgenic
animals of the prior art in that it carries a
non-infectious transgene having the complete
coding sequence of the HIV genome, the transgene
being capable of producing high levels of HIV
proteins in several tissues and certain body
fluids of the animal. The attainment of the
present transgenic mammal is surprising indeed in
view of previous reports that expression of HIV
proteins was found to be very low in mouse
fibroblasts transfected with the HIV genome; for
example, see J.A. Levy et al., Science, 232, 998
(1986).

Summary of the Invention

The present invention provides a non-human transgenic mammal in which the germ cells and somatic cells carry a transgene capable of expressing non-infectious HIV-1 ribonucleic acid (HIV-1 RNA) and complementary proteins in the cells. The transgene is introduced into the animal, or an ancestor of the animal, at an embryonic stage, preferably between the one-cell (or fertilized oocyte) and the 8-cell stage.

Among the expressed complementary proteins, which can be found in the milk, serum and several tissues of the transgenic animal are the gag and envelope proteins.

A noteworthy feature of the present transgenic animal is that it can produce progeny in which the gene is stably expressed. Hence, animal lines of the transgenic animal, having the same essential characteristics, are realized.

The transgene of the transgenic animal of this invention comprises (a) a non-infectious HIV-1 proviral DNA sequence, (b) a surrogate promotor DNA sequence operatively linked to a tissue-specific DNA sequence to provide a surrogate promoter/tissue-specific enhancer, which in turn is operatively linked to the proviral DNA sequence, and (c) at least one polyadenylation addition signal DNA sequence operatively linked to the proviral DNA sequence.

A preferred embodiment of the transgene for use in the animal comprises (a) a proviral DNA sequence, coding for HIV-1 RNA, in which the 5'-

long terminal repeat (5'-LTR) sequence, a portion of the 5' leader sequence and a portion of the 3'-long terminal repeat (3'-LTR) have been deleted, the deleted portions being predetermined to render non-infectious any HIV-1 RNA and complementary proteins expressed within the cells of the animal; (b) a surrogate promoter/tissue-specific enhancer DNA sequence operatively linked to the 5'-end of the proviral DNA sequence to drive the RNA expression of the transgene in a preselected tissue of the animal; and (c) one or more polyadenylation (poly A) addition signal sequences, operatively linked at the 3' end of the proviral DNA to provide 3' maturation and stabilization of the expressed RNA.

In a more preferred embodiment of the transgene, the surrogate promoter/tissue-specific enhancer sequence is the LTR promoter of the mouse mammary tumor virus (MMTV), also known as MMTV LTR, and the poly A addition signal sequence is the SV40 poly A addition signal.

Disclosed hereinafter are a process for preparing the aforementioned transgene from a recombinant DNA plasmid in which the DNA sequence of the transgene has been incorporated therein, and in turn a process for preparing the plasmid. The processes and the plasmid are included within the scope of this invention.

Also included within the scope of the invention is a method of producing a transgenic animal, carrying the aforementioned transgene, which can be stably bred to produce offspring containing the gene. The method comprises:

(a) isolating a fertilized oocyte from a first female animal;

(b) transferring the transgene into the fertilized oocyte;

5 (c) transferring the fertilized oocyte containing the transgene to the uterus of the same species as the first animal;

(d) maintaining the second female animal such that

10 (i) the second female animal becomes pregnant with the embryo derived from the fertilized oocyte containing the transgene,

(ii) the embryo develops into the transgenic animal, and

15 (iii) the transgenic animal is viably born from the second female animal;

wherein the transgenic animal has the genetic sequence for non-infectious HIV proviral DNA and is capable of being bred to produce
20 offspring having cells stably containing the genetic sequence.

Noteworthy is that by monitoring the effect of a test compound on the levels of expressed non-infectious RNA, and the translated proteins
25 therefrom, e.g. the gag and envelope proteins and the gag protein cleavage products, the therapeutic value of a test compound for treating HIV infections in humans can be evaluated.

For instance, the proteins expressed in the cells of the transgenic animal include processed gag proteins resulting from the cleavage of the HIV-1 encoded gag-pol gene, the cleavage being effected by the HIV-1 encoded protease. Thus, the invention also provides a method for evaluating a test compound as a potential HIV-1 protease inhibitor. The method involves:

(a) administering the test compound to the transgenic animal, and

(b) examining the effect or significance of the test compound on the expressed gag proteins in the animal by monitoring the expression levels of the proteins.

Likewise, since the presence of the gag and envelope proteins in the fluid and tissues of the transgenic animal denotes that the HIV regulatory protein, REV, is expressed, the present invention provides a method for evaluating a test compound as a potential inhibitor of REV function. The method involves:

(a) administering the test compound to the transgenic animal, and

(b) examining the effect or significance of the test compound on the expressed gag and envelope proteins and the gag protein cleavage products in the animal by monitering the expression levels thereof.

Still another aspect of this invention involves the use of the transgenic animal for the production and isolation of the non-infectious RNA and its complementary proteins.

2042625

Description of the Drawings

Figure 1 is a diagrammatic representation of a region of a plasmid bearing the non-infectious HIV proviral DNA sequence and flanking regions. The restriction sites are A, AatII; B, BamH1; E, EcoR1; H, HindIII; S, SacI; and X, XbaI.

Figure 2 is a reproduction of a photograph of a Western blot analysis of human T-cells infected with HIV-1 (lane 1), milk from representative female transgenic mice of this invention (lanes 2 and 4) and milk from normal C3H mice (lanes 3 and 5). The HIV gag proteins are similarly processed in human T-cells and in the transgenic mouse. No HIV-specific proteins are detected in the milk of the normal mouse.

Details of the Invention

The term "HIV" and "HIV-1" are used interchangably herein and refer to the human immunodeficiency virus type 1. It should be noted, however, that the technology of the present application can be adapted to produce a transgenic animal carrying a transgene expressing HIV-2 RNA. Accordingly, the latter transgenic animal is deemed to be within the scope of this invention.

The term "gene" as used herein means the smallest, independently functioning DNA sequence which encodes for a protein product. An example of a gene is the DNA sequence which encodes for the gag protein.

The term "transgene" as used herein means exogenous genetic material which does not naturally form part of the genetic material of an animal to be genetically altered but can be 5 incorporated into the germ and somatic cells of that animal by standard transgenic techniques. The transgene of the present invention is created by the serial ligation of a promoter DNA segment, a major portion of the HIV-1 genome including the 10 coding region for gag-pol and envelope, and at least one poly A addition DNA sequence.

The term "operatively linked" as used herein in reference to units (i.e. distinguishable DNA sequences) of a transgene, means that the units 15 to which the term is applied are linked according to recombinant technology techniques so that they may act together to control and express the transgene encoded RNA in a suitable tissue or cell type. An example would be the operatively 20 linking of a promotor/tissue-specific enhancer to a DNA sequence coding for the desired proteins so as to permit and control expression of the DNA sequence and the production of the complementary proteins.

25 The term "promoter" as used herein means a DNA sequence which binds RNA polymerase and directs the enzyme to the correct transciptional start site. The promoter is upstream of the HIV proviral DNA sequence to which it is operatively 30 linked.

The term "enhancer" as used herein refers to a DNA sequence capable of increasing the transcription of the promoter. The term "promoter/tissue-specific enhancer" means a DNA

sequence, having an activation site which is capable of being activated in a specific tissue or specific cell type, to promote the preferential transcription of a given gene to which the DNA sequence is operatively linked. Thus the transciption and expression of the transgene having the promoter/tissue-specific sequence will be enhanced within the specific tissue or cell-type. Examples of promoter/tissue-specific enhancers are the aforementioned MMTV LTR and the promoter/brain-specific enhancer, the myelin basic protein (MBP) promoter.

The term "complementary proteins" or "associated proteins" as used herein in relation to HIV-1 RNA refers to the initially translated proteins and their subsequent cleavage products. In particular, the term refers to the readily isolated and detectable proteins such as the HIV-1 gag protein (p55), the HIV-1 gag protein cleavage products p24 and p17, the envelope glycoprotein gp160 and the envelope protein cleavage product gp120.

As indicated previously, procedures for producing transgenic animals have advanced considerably during the last ten years. This advance has provided new avenues for seeking improvement and creative applications. A compendium of the techniques can be found in the textbook by B. Hogan et al. entitled "Manipulating the Mouse Embryo: A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1986). The latter reference is incorporated herein by reference.

More explicitly with regard to the present invention, the key feature is the realization of an animal carrying a transgene expressing non-infectious HIV-1 RNA, which in turn is translated to give complementary HIV proteins in its body fluids and tissues.

Any mammal may be used in the production of the transgenic animal of this invention. The choice of animal will depend on the particular use planned for the transgenic animal.

When it is envisaged to use the transgenic animal as a model to study or evaluate the effects of a test compound on the expression of the HIV RNA and its complementary proteins, the practical choice of animal is one that is small, inexpensive and breeds readily and rapidly. In this case, the practical choice is a rodent, preferably a rat or a mouse. As noted in B. Hogan et al., *supra*, the mouse has been the favored small animal for the development and applications of transgenic technology; however the rat is also a practical animal species for this purpose; for example, see R.E. Hammer et al., Cell, 63, 1099 (1990).

When it is envisaged to use the transgenic animal as a source of HIV-1 RNA and its complementary proteins, i.e. for the production of research quantities of the non-infectious RNA transcript and associated proteins, e.g. gp160, gp120, p55, p41, p24, p17, REV, etc., a larger animal can be used. A convenient and practical process for such production purposes comprises the use of mammals that have long lactating periods and produce large volumes of milk; for

example cows, sheeps, goats and pigs, which are genetically altered with a transgene of this invention so that the desired products are secreted into the mammal's milk. In this instance the transgene comprises a promoter/tissue-specific enhancer which is a mammary tissue specific promoter, or any promoter sequence known to be activated in mammary tissue, operatively linked to the non-infectious HIV proviral DNA sequence. The desired products are isolated from the collected milk of the animal by standard procedures.

More explicitly with regard to the construction of the present recombinant transgene, the transgene comprises three fragments: firstly, a proviral DNA sequence having deleted portions at its 5′ and 3′ ends so as to render non-infectious the expressed HIV RNA and complementary proteins; secondly, a surrogate promoter/tissue-specific enhancer DNA sequence to drive the expression of the proviral DNA sequence; and thirdly, one or more poly A addition signal DNA sequences.

The promoter/tissue-specific enhancer is located upstream from the proviral DNA sequence; and the poly A addition signal sequence is located downstream of the proviral DNA sequence.

The HIV proviral DNA sequence is prepared by digesting a plasmid clone containing the DNA sequence of HIV-1 with a restriction enzyme that cleaves the HIV proviral DNA sequence at sites proximal to its 5′ and 3′ ends, removing essential controling sequences, to give a proviral DNA sequence truncated at both ends so that the

eventual RNA expression from the cleaved fragment is rendered non-infectious, but still includes those elements required for the eventual production of the complementary proteins. In other words, the HIV genome lacks the sequences necessary for reverse transcription, integration and transcription. [The extent to which the $5'$ and $3'$ ends must be truncated to render the RNA non-infectious can be determined by standard methods; for example, by transforming the fragment so obtained into a genomic equivalent of HIV-1 and testing the resulting virus for cytopathic activity.] For example, a particular plasmid and restriction enzyme for effecting this result is the pBH10 plasmid [B.H. Hahn et al., Nature, 312, 166 (1984)] and the restriction enzyme SacI. The latter restriction enzyme cleaves the plasmid to give an HIV-1 genome deleted of its $5'$ LTR, part of its untranslated $5'$ leader sequence and a portion of its $3'$ end LTR.

Concerning the surrogate promoter/tissue-specific enhancers useful in various embodiments of this invention, any such promoter/enhancer which effectively drives the expression of the non-infectious HIV genome can be used. The choice of the promoter/enhancer depends on the tissue or tissues in which it is desired to express the HIV RNA and associated proteins. For instance, if it is desired to express the desired products in the milk, promoters which are known to be activated in the mammary gland are employed. Examples of such milk specific protein promoters are the casein promoters and the β-lactoglobin promoter. Among the promoters that are specifically activated in the milk and thus useful for expressing the desired products in

milk according to the present invention is the MMTV LTR. By way of another example of promoters, when it is desired to specifically express the non-infectious RNA and associated proteins in the brain of the transgenic animal, promoters which are known to be activated in the brain are incorporated into the transgene. Such animals provide a useful in vivo model to evaluate the ability of a potential anti-HIV drug to cross the blood-brain barrier. An example of brain-specific protein promoter is the myelin basic protein (MBP) promoter.

In a preferred embodiment of the transgene, the surrogate promoter/tissue-specific enhancer to drive expression of the HIV genome is the mouse mammary tumor virus long terminal repeat (MMTV LTR) sequence. This promoter is known to be tissue specific toward various epithelial and hemopoietic tissues, some of which naturally support lentivirus (and especially HIV) replication.

Concerning the poly A addition signal sequence, this fragment is one or a tandem of two to four of the known poly A addition signal sequences, such as those derived from the SV40 genome, the casein $3'$ untranslated region or other $3'$ untranslated sequences known in the art. A convenient and readily available source for the poly A addition signal is the commercially available pSV2neo vector from which the SV40 poly A addition signal sequence can be cleaved.

The transgene can be prepared from the aforementioned three fragment by using techniques known in the art; for example see J. Sambrook et

al., "Molecular Cloning: A Laboratory Manual",
2nd ed, Vols 1 to 3, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY, USA,
1989, herein incorporated by reference. More
5   specifically, the three fragments can be ligated
together with T4 DNA ligase in the presence of a
restriction   endonucleas-digested   vector   to
produce   the   gene-carrying   plasmid   with   the
desired orientation of the fragments, i.e. so
10   that they are operatively linked. Subsequent
cleavage of the latter plasmid at appropriate
unique   sites   is   effected   by   restriction
endonucleases to excise the linear transgene,
which   after   appropriate   purification   is
15   incorporated into the animal to be genetically
altered.

The linear transgene (hereinafter sometimes
referred to as the MMTV/HIV fragment) can be
added to the gene pool of the animal to be
20   altered by incorporating one or more copies of
the transgene into the genome of a mammalian
embryo by techniques known in the art.   A
practical technique is to introduce the transgene
at   the   embryonic   stage   of   the   animal   by
25   microinjecting the transgene into a fertilized
oocyte of the animal between the one-cell and
eight-cell stage, preferably between the one-
cell and four-cell stage.   In this manner,
between 5 to 30% of the animals developing from
30   such oocytes contain at least one copy of the
transgene in somatic and germ cells, and these
founder animals transmit stably the transgene
through the germ line to the next generation.

The   biological   profile   of   the   present
35   transgenic animal renders it useful as an animal

model for studying HIV/host cell interactions and for evaluating potential anti-HIV agents acting at a post-integration step of the HIV life cycle. On the basis that the main structural gag proteins, e.g. p55, p41 and p24, are expressed in the animal cells, potential HIV-1 protease inhibitors can be evaluated since the HIV protease is essential for the processing of mature proteins from the gag-pol polyprotein. The presence of the RNA transcript and the presence or decrease (or disappearance) in the processed proteins in the cells serves as a means for evaluating HIV protease inhibitors.

On the basis that the main structural HIV proteins are properly made, especially the gag and envelope proteins and the gag cleavage products, potential REV function inhibitors can be evaluated since the REV function is essential for the production of those proteins. Thus, the monitoring of the levels of the latter proteins in the cells of the transgenic animal receiving a test agent provides a means for evaluating the anti-REV function activity of the agent.

Likewise, a potential inhibitor of cellular protease required for the processing of envelope glycoproteins, can be detected by monitoring the levels of gag and envelope proteins. In this instance, the cellular protease inhibitor does not affect the cellular levels of gag proteins but it does decrease the levels of the mature envelope glycoproteins, e.g. gp120, or cause their disappearance from the body cells. Thus, the comparative effects on the translation of gag and envelope proteins serves as an indication of cellular protease inhibition.

The following examples further illustrate this invention.

Example 1

Construction of Transgene (12 kbp MMTV/HIV fragment)

5   The transgene consisted of three fragments; the **MMTV** LTR promoter/tissue-specific enhancer sequence, the HIV proviral DNA sequence and the poly A addition signal sequence. The fragments were prepared as follows:

10   (a) MMTV LTR promoter sequence - The 2.3 (kbp) BamH1 MMTV fragment containing the $3'$ end sequences of the MMTV genome (including the $3'$ env sequences with the whole $3'$ end LTR) was obtained by digestion of plasmid pA9, A.L. Huang

15   et al., Cell, 27, 245 (1981), followed by subcloning of the resulting fragment at the BamH1 site of plasmid pUC18 in an orientation which placed the end of the LTR close to the EcoR1 site. It was then prepared as a HindIII - SacI

20   fragment by digestion with the restriction enzyme HindIII and then a partial digestion with the restriction enzyme SacI. Thus both of the enzymatic sites of the fragment were derived from the polylinker of the vector.

25   (b) HIV proviral DNA sequence - The 8.9 kbp SacI HIV-1 fragment was obtained by digesting the plasmid pBH10, B.H. Hahn et al., Nature, 312, 166 (1984), with SacI.

       (c) poly A addition signal sequence - The SV40

30   poly A addition signal was prepared by cleaving the 885 bp BamH1 - PstI fragment from the pSV2neo vector (ATCC 37149) and subcloning the fragment

so obtained in the plasmid pUC18 (ATCC 37253).
The SV40 fragment was then prepared from the
subclone by digesting the subclone with SacI and
HindIII.

5   Using T4DNA ligase, the three fragments from
sections (a), (b) and (c) were ligated together
in a HindIII-digested pBR322 vector in an
orientation which placed the $3'$ end SV40
sequences close to the EcoR1 site of the plasmid
10   pBR322. (See J. Sambrook et al., *supra*, section
1.12, for a description of pBR322.) In this
manner, the gene-carrying pBR322 plasmid,
incorporating the transgene DNA sequence (i.e.
the 12 kbp MMTV/HIV fragment), was obtained.
15   This plasmid is diagrammatically represented by
Figure 1.

       The 12 kbp MMTV/HIV fragment for
microinjection, see example 2, was obtained by
cleaving the gene-carrying pBR322 plasmid with
20   restriction enzymes XbaI and AatII. The fragment
was isolated by agarose gel electrophoresis and
further purified on CsCl gradients, essentially
as described by B. Hogan et al., *supra*, p 159.

In this manner, the 12 Kbp MMTV/HIV fragment was
25   obtained wherein the proviral DNA sequence
therein lacks the $5'$-LTR sequence, a portion of
the $5'$-leader sequence and a portion of the
$3'$-LTR, thus rendering the fragment non-
infectious.

30   ## Example 2
Construction of Transgenic Mice

       One-cell (C57BL/6 x C3H)F2 embryos were
collected, microinjected with the 12 Kbp MMTV/HIV
fragment of example 1 (weight concentration = ca

1 µg/mL) and transferred into pseudopregnant CD-1 females essentially as described before [Hogan et al., *supra* and L. Bouchard et al., Cell, <u>57</u>, 931 (1989)]. From 85 eggs, microinjected with the fragment and reimplanted, 17 mice were born, four of which were later found to be transgenic by Southern blot analysis of tail DNA with a ^{32}P-HIV-1 specific probe (see J. Sambrook et al, *supra*, sections 9.31 to 9.57).

The HIV-specific probe was prepared by labeling the aforementioned 8.9 kbp SacI HIV-1 fragment with ^{32}P-deoxycytosine triphosphate and deoxyadenosine triphosphate by the random primer method (see J. Sambrook et al., *supra*, section 10.13).

In each of the four transgenic mice, the MMTV/HIV sequences appeared intact and localized at an unique integration site (data not shown).

Three of the transgenic mice were bred successfully to C3H mice, obtained from Charles River Laboratories Canada Inc., St-Constant, Québec, Canada. These three founders transmitted the transgene to their progeny in a Mendelian fashion. The three lines, i.e. MMTV/HIV-R3, MMTV/HIV-R4 and MMTV/HIV-R10, were thus established by mating founder mice to C3H mice.

Example 3
Transgenic Mouse Studies

(a)   **Phenotype of mice carrying the MMTV/HIV transgene**

5   No phenotype was apparent in the transgenic mice. They looked, behaved and moved like the age-matched, non-transgenic mice. At autopsy, macroscopic examination of the transgenic mice indicated that they were normal.

10   (b)   **RNA transcript**

         HIV-1 RNA expression of the transgene was detected by the agarose gel transfer (Northern) procedure, using total RNA from various organs of representative transgenic mice.

15   More particularly, the total RNA was isolated by the method of P. Chomczynski and N. Sacchi, Anal. Biochem., 162, 156 (1987) and analyzed by the Northern blot procedure (see J. Sambrook et al., *supra*, section 7.39). RNA was

20   separated on 1% formaldehyde-agarose gels, transferred to nylon membranes (Hybond-N®, Amersham Canada Ltd., Oakville, Ontario, Canada) and hybridized with the aforementioned ^{32}P-HIV-specific probe according to the method of

25   L. Singer and K.W. Jones, Nucl. Acids Res., 12, 5627 (1984).

         The three main species of HIV-1 RNA (classified according to their molecular weight), usually detected in cells productively infected

30   with HIV-1, were detected in several organs known to support transcription from the MMTV LTR, such

as mammary, Harderian and salivary glands, epididymis, thymus and spleen, in the three transgenic lines tested. Additional investigations were carried out on other organs

5 of the mice of the line MMTV/HIV-R10. In those organs which are known to support MMTV-LTR-driven transcription poorly, such as the kidney, liver or brain, the examination of the organs for transgene RNA transcript indicated that the

10 transgene was not expressed, as expected.

(c) Expression of HIV structural protein in organs of the transgenic mice.

To determine whether the HIV-1 RNA found in organs of the transgenic mice was translated, the

15 levels of HIV structural proteins in these organs were measured by the Western blotting procedure (see E. Harlow and D. Lane, "Antibodies : A Laboratory Manual", Cold Springs Harbor Laboratory, Cold Springs Harbor, NY, USA, 1988,

20 section 12) with antisera specific to HIV-1 proteins. The env gp160 and gp120 were detected at very high or moderate levels in the mammary glands of animals of three transgenic lines, at lower levels in the salivary and Harderian

25 glands, and in the liver, seminal vesicles, epididymis and testis of mice from the line MMTV/HIV-R10, and in the epididymis, spleens or livers of mice from line MMTV/HIV-R4. These proteins comigrated with authentic HIV env

30 proteins from HIV-1 infected cells, except that the transgenic gp120 migrated slightly faster.

The gag p55 precursor protein was detected at high levels in mammary glands of animals of the three transgenic lines. The p55 and/or p41

proteins were detected in the salivary and Harderian glands, and in the spleen, seminal vesicles and epididymis of mice from line M/HIV-R10 and in the spleen and epididymis of mice from line MMTV/HIV-R4. The mature cleavage product, the p24 gag protein was detected in mammary glands of mice from line MMTV/HIV-R10 and MMTV/HIV-R3 and in the salivary glands of animals from line MMTV/HIV-R10. The p55, p41 and the p24 proteins from the above designated organs of the transgenic mice migrated with corresponding authentic proteins from HIV-1 infected human T-cells, indicating proper synthesis and cleavage in these mouse organs.

In serum, HIV-1 proteins reactive with HIV-specific antibodies were detected in mice from two lines (MMTV/HIV-R4 and MMTV/HIV-R10). Higher levels of HIV-1 serum proteins were detected in lactating female mice.

The HIV env (gp 160 and gp 120) and gag (p55, p41 and p24) proteins were also detected at very high levels in milk from lactating female transgenic mice (see Figure 2). In addition, HIV proteins were detected at a lower level in the secretions of the male genital tract. These results were expected since the mammary glands as well as the epididymis were positive for HIV-1 proteins, see above.

These results clearly indicated that several mouse specialized cell types are capable of releasing HIV proteins extracellularly either in the circulation or in secretions.

Search for the presence of MuLV(HIV) or HIV(MuLV) pseudotypes in serum of transgenic mice.

HIV and murine leukemia viruses (MuLV) have been shown to form pseudotypes under certain experimental conditions. Although a short leader sequence necessary for HIV RNA packaging is still present in the transgene, the HIV RNA sequences transcribed in these mice would not be expected to be packaged very efficiently, due to the absence of other leader and LTR sequences. Moreover, if packaged, these sequences would not be expected to be reverse transcribed, because of the absence of U5, R5 and part of the U3 and R3 sequences of HIV-1. HIV proteins, however, should be able to form pseudotypes with MuLV proteins and may be able to package endogenous MuLV RNA.

To detect infectious particles having a MuLV RNA genome and HIV env proteins, A3.01 cells, known to be resistant to ecotropic and xenotropic MuLV infection but sensitive to MuLV replication and harboring the CD4 receptor for HIV, were used. These human cells, possibly infected and producing MuLV, were cocultivated with NIH/3T3 or mink cells, respectively susceptible to ecotropic or xenotropic MuLV. No such MuLV (HIV) ecotropic or xenotropic pseudotype was detected in serum of the transgenic mice from lines MMTV/HIV-R4 and MMTV/HIV-R10 indicating that these pseudotypes were absent or below the sensitivity of the assay.

Therefore, it appears that the formation of MuLV (HIV) pseudotypes is not characteristic of these transgenic mice.

In conclusion, the transgenic animal of the
invention therefore provides a safe and practical
model to study the effects of test compounds,
when administered systemically to the animal, on
the expressed HIV RNA, processed gag proteins,
the pol encoded enzymes, envelope proteins and
regulatory proteins (e.g. REV). For instance,
the readily measurable high levels of the HIV-1
gag reactive proteins, p55, p41 and p24, in the
milk of the lactating female transgenic mice,
noted above, renders the latter animal a
convincing and practical model for evaluating a
test compound as a HIV-1 protease inhibitor by
administering the test compound, po, sc, ip or
iv, to the animal, and monitoring the effect of
the test compound on the expression levels of the
HIV-1 gag reactive proteins in the milk of the
animal, for example, by the Western blotting
procedure utilizing a gag p24 or p17 specific
antibodies.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1.   A non-human transgenic mammal in which the germ cells and somatic cells carry a transgene capable of expressing non-infectious HIV-1 RNA and complementary proteins in the cells, the transgene being introduced into the mammal, or an ancestor thereof, at an embryonic stage.

2.   The mammal of claim 1 wherein the transgene comprises (a) a non-infectious HIV-1 proviral DNA sequence, (b) a surrogate promoter/tissue-specific enhancer operatively linked to the proviral DNA sequence, and (c) at least one poly A addition signal DNA sequence operatively linked to the proviral DNA sequence.

3.   The mammal of claim 1 wherein the transgene comprises:

(a)   a proviral DNA sequence, coding for HIV-1 RNA, in which the 5'-LTR sequence, a portion of the 5' leader sequence and a portion of the 3'-LTR have been deleted, the deleted portions being predetermined to render non-infectious any expressed HIV-1 RNA or complementary proteins thereof;

(b)   a surrogate promoter/tissue-specific enhancer DNA sequence operatively linked to the 5'-end of the proviral DNA sequence to drive the RNA expression of the transgene in a preselected tissue of the animal; and

(c) one or more poly A addition signal DNA sequences, operatively linked at the 3$'$ end of the proviral DNA sequence to provide 3$'$ maturation and stabilization of the expressed RNA.

4.   The mammal of claim 2 wherein the surrogate promoter/tissue-specific enhancer is the MMTV LTR promoter and the poly A addition signal sequence is the SV40 poly A addition signal.

5.   The mammal of any one of claims 1 to 4 wherein the mammal is selected from a cow, sheep, goat, pig, rat and mouse.

6.   The mammal of any one of claims 1 to 4 wherein the mammal is a mouse.

7.   The recombinant transgene as recited in any one of claims 2 to 4.

8.   A process for preparing a transgene comprising the following three DNA sequences: (a) a proviral HIV DNA sequence having a deleted portion at its 5$'$ and 3$'$ ends so as to render non-infectious expressed HIV RNA and complementary proteins therefrom; (b) a surrogate promoter/tissue-specific enhancer DNA sequence, operatively linked to the 5$'$-end of the proviral DNA sequence; and (c) one or more poly A addition signal DNA sequences operatively linked to the 3$'$ end of the proviral DNA; said process comprising; ligating in the desired orientation the three DNA sequences into a restriction endonuclease-digested vector to obtain the corresponding gene-carrying plasmid and cleaving the plasmid at unique sites with restriction endonucleases to excise the transgene.

9. A gene-carrying plasmid when prepared by ligating in the desired orientation the three fragments of claim 8 into a restriction endonuclease-digested vector.

5   10. A gene-carrying plasmid when prepared by ligating in the desired orientation the three fragments as defined in claim 8 into a HindIII-digested pBR322 vector.

11. A method for producing a transgenic mammal
10   of claim 2, comprising:

(a) isolating a fertilized oocyte from a first female animal;

(b) transferring the transgene of claim 2 into the fertilized oocyte;
15   (c) transferring the fertilized oocyte containing the transgene to the uterus of the same species as the first animal;

(d) maintaining the second female animal such that
20   (i) the second female animal becomes pregnant with the embryo derived from the fertilized oocyte containing the transgene,
        (ii) the embryo develops into the transgenic animal, and
25   (iii) the transgenic animal is viably born from the second female animal;
        wherein the transgenic animal has the genetic sequence for non-infectious HIV-1 proviral DNA and is capable of being bred to
30   produce offspring having cells stably containing the genetic sequence.

12. A method for evaluating a test compound as a potential HIV-1 protease inhibitor, comprising:

(a) administering the test compound to the transgenic animal of claim 1, and

(b) examining the effect or significance of the test compound on the expressed gag proteins in the animal by monitoring the expression levels thereof.

13. A method for evaluating a test compound as a potential inhibitor of REV function, comprising:

(a) administering the test compound to the transgenic animal of claim 1, and

(b) examining the effect or significance of the test compound on the expressed gag and envelope proteins and the gag protein cleavage products in the animal by monitoring the expression levels thereof.

14. A process for the production of non-infectious HIV-1 RNA or the complementary proteins thereof, comprising:

a) collecting the milk from the transgenic animal of claim 2 wherein in the promoter/tissue-specific enhancer DNA sequence is a mammary tissue specific promoter;

b) collecting the milk, and

c) isolating the non-infectious HIV-1 RNA, or the complementary proteins thereof, from the milk.

FIGURE 1

FIGURE 2